AbbVie (ABBV) Revenue Growth (3y) (2015 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Revenue Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
41.69% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
4.82% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
7.06% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
3.98% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
12.18% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
3.09% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-13.60% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
0.44% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
7.06% |
| Dec 31, 2025 |
3.20% |
| Sep 30, 2025 |
2.12% |
| Jun 30, 2025 |
1.88% |
| Mar 31, 2025 |
-0.48% |
| Dec 31, 2024 |
0.48% |
| Sep 30, 2024 |
0.27% |
| Jun 30, 2024 |
1.19% |
| Mar 31, 2024 |
-1.83% |
| Dec 31, 2023 |
1.05% |
| Sep 30, 2023 |
2.58% |
| Jun 30, 2023 |
9.97% |
| Mar 31, 2023 |
12.36% |
| Dec 31, 2022 |
20.21% |
| Sep 30, 2022 |
20.44% |
| Jun 30, 2022 |
20.89% |
| Mar 31, 2022 |
20.03% |
| Dec 31, 2021 |
21.47% |
| Sep 30, 2021 |
20.31% |
| Jun 30, 2021 |
19.03% |
| Mar 31, 2021 |
17.92% |
| Dec 31, 2020 |
21.43% |
| Sep 30, 2020 |
22.64% |
| Jun 30, 2020 |
14.50% |
| Mar 31, 2020 |
9.65% |
| Dec 31, 2019 |
8.60% |
| Sep 30, 2019 |
9.65% |
| Jun 30, 2019 |
8.56% |
| Mar 31, 2019 |
9.53% |
| Dec 31, 2018 |
9.07% |
| Sep 30, 2018 |
11.48% |
| Jun 30, 2018 |
326.10% |
| Mar 31, 2018 |
16.33% |
| Dec 31, 2017 |
12.39% |
| Sep 30, 2017 |
11.70% |
| Jun 30, 2017 |
12.13% |
| Mar 31, 2017 |
12.74% |
| Dec 31, 2016 |
9.96% |
| Sep 30, 2016 |
11.36% |
| Jun 30, 2016 |
11.20% |
| Mar 31, 2016 |
11.23% |
| Dec 31, 2015 |
7.13% |
| Sep 30, 2015 |
9.66% |
| Jun 30, 2015 |
-71.23% |
| Mar 31, 2015 |
6.49% |
